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developed for the treatment of atrial ﬁbrillation (AF).
OBJECTIVES The purpose of this study was to investigate the effects
of the highly selective Kv1.5 inhibitor XEN-D0103 on human atrial
action potentials (APs) at high excitation rates and to assess safety.
METHODS Intracellular APs (stimulation rates 1–5 Hz) were
measured in right atrial trabeculae from patients in sinus rhythm
(SR), chronic AF (cAF; AF of46 months duration), and paroxysmal
AF (pAF). The safety and tolerability of XEN-D0103 were tested in a
double-blind, randomized, placebo-controlled phase 1 study.
RESULTS Depending on its concentration, XEN-D0103 elevated the
plateau potential. At 1 Hz, XEN-D0103 (3 mM) shortened action
potential duration at 90% repolarization (APD90) and effective
refractory period (ERP) in SR preparations, but prolonged these
parameters in cAF preparations. In SR and pAF preparations, the
shortening effects on APD90 and ERP turned into prolongation at
high rates. In cAF trabeculae, XEN-D0103 prolonged APD90 and ERP
at 2 and 3 Hz. At high rates, more SR and pAF preparations failed to
capture excitation in the presence of the drug than in its absence.
XEN-D0103 (10 mM) did not signiﬁcantly affect human ventricular
APs. Even with plasma concentrations reaching 7000 ng/mL, XEN-
D0103 did not increase ΔΔQTcF (QT interval corrected by the
Fridericia formula) in the analysis of electrocardiograms of healthy
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CONCLUSION APD prolongation and suppression of APs by XEN-
D0103 at high stimulation rates in SR and pAF tissue, but not cAF,
could be of therapeutic beneﬁt for reducing AF burden. This
concept needs to be conﬁrmed in clinical trials.
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ABBREVIATIONS AF ¼ atrial ﬁbrillation; ANOVA ¼ analysis of
variance; AP¼ action potential; APA¼ action potential amplitude;
APD20, APD50, APD90 ¼ action potential duration at 20%, 50%,
and 90% of repolarization; cAF ¼ chronic atrial ﬁbrillation;
DMSO ¼ dimethyl sulfoxide; dV/dtmax ¼ maximum upstroke
velocity; ECG ¼ electrocardiogram/electrocardiographic; ERP ¼
effective refractory period; HR ¼ heart rate; IKur ¼ ultra-rapidly
activating delayed-rectiﬁer potassium current; pAF ¼ paroxysmal
atrial ﬁbrillation; PLT20¼ plateau potential, that is, mean absolute
membrane potential (mV) in the time window between 20% and
30% of APD90; QT ¼ corrected QT; QTcF ¼ QT interval corrected by
the Fridericia formula; RMP ¼ resting membrane potential; SR ¼
sinus rhythm; TMC ¼ time-matched control
(Heart Rhythm 2016;13:555–564) I 2016 Heart Rhythm Society.
Open access under CC BY-NC-ND license.Introduction
Drug treatment of atrial ﬁbrillation (AF) aims to prevent
stroke and restore and maintain sinus rhythm (SR). Exper-
imental and clinical evidence suggest that AF is due to
microreentry triggered by ectopic foci located in the prox-
imity of the pulmonary veins1; hence, Naþ channel blockers
(class I) for reducing excitability and Kþ channel blockers
for prolongation of the action potential duration (APD) and
effective refractory period (ERP) (class III)2 are accepted
therapeutic options. The multi-ion channel blocker amiodar-
one is currently the most efﬁcacious antiarrhythmic agent forhttp://dx.doi.org/10.1016/j.hrthm.2015.10.003
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is poorly tolerated. Current AF drugs lack atrial speciﬁcity,
producing proarrhythmic liability in the ventricles that can
lead to torsades de pointes and sudden cardiac death.3 Thus,
there is a clear unmet medical need for new pharmacological
AF therapies with improved efﬁcacy and safety.4
The ultra-rapidly activating delayed-rectiﬁer potassium
current (IKur) conducted by the Kv1.5 protein is a novel drug
target because this channel is hardly expressed in ven-
tricles.5–7 Therefore, selective inhibitors of IKur are expected
to prolong atrial but not ventricular ERP and should be
devoid of risk for ventricular proarrhythmia.
We have previously investigated the electrophysiological
effects of several modestly selective IKur inhibitors, that is, 4-
aminopyridine (low concentration), AVE0118, XEN-D0101,
and MK-0448, all of which elevated the plateau phase of
human atrial action potentials (APs) recorded in trabeculae
of right atrial appendages of patients in SR or AF.8–11
Interestingly, the expected actions of a Kþ channel blocker,
that is, prolongation of APD/ERP, were observed only in AF
preparations, whereas in SR preparations these parameters
were shortened.8–11 Those experiments were performed with
a stimulation frequency of 1 Hz (60 beats/min); however, it is
unknown how IKur inhibitors affect human atrial APs at
higher excitation rates as encountered in AF (ie, 228–440
beta/min, 4–8 Hz12).
The Kv1.5 inhibitor MK-0448 failed to affect ERP in
young healthy volunteers,13 and the authors concluded that
IKur block cannot be expected to exert therapeutically useful
antiarrhythmic effects in AF. However, only rather long
cycle lengths could be tested (Z400 ms,r150 beats/min),13
but like many conventional antiarrhythmic drugs, IKur inhib-
itors, too, could exhibit frequency-dependent actions.
We have published a preliminary report that XEN-D0103
(Servier S66913) selectively blocks human IKur and recombi-
nant hKv1.5 current in CHO cells stably expressing the
hKCNA5 gene.14 Since the effects of IKur inhibitors onFigure 1 Schematic of the experimental procedure for action potential measurem
an equilibration period of Z60 minutes at a stimulation rate of 1 Hz, the effectiv
successively, with 2 minutes for stabilization (a) and 2 minutes for the measureme
were exposed to XEN-D0103 for 60 minutes before going through another set ofex vivo human atrial tissue paced at pathophysiological
frequencies are unknown, the purpose of this study was
to evaluate the effects of XEN-D0103 on atrial APs and
ERP at normal and AF relevant frequencies (1–5 Hz)
with standard microelectrode techniques in isolated atrial
trabeculae from patients in SR and chronic AF (cAF) or
paroxysmal AF (pAF). The safety and tolerability of XEN-
D0103 were determined in a phase 1 study performed in
healthy volunteers.
Methods
Studies reported here conform to the principles outlined in the
Declaration of Helsinki and were reviewed and approved by
relevant ethics committees; all human subjects gave written
informed consent. Atrial tissue was obtained from patients
receiving cardiac surgery (ethic committee approval number
of TUDresden: EK790799). The characteristics of the patients
are summarized in Online Supplemental Table S1. The AP
study included 22 preparations from patients in SR (SR
group), 19 preparations from 17 patients in permanent AF
(deﬁned as cAF for46 month at the time of tissue collection),
and 12 preparations from 11 patients in pAF (episodes of AF
terminating spontaneously within 7 days).
In vitro AP and ERP measurements
APs were measured with a sharp microelectrode (tip
resistances 20–80 MΩ) in small pieces of right atrial
appendages at 361C11C, as described previously.9,11 The
basal rate of stimulation was 1 Hz. Each experiment was
preceded by a 60-minute equilibration period during which
the preparations were allowed to stabilize. Small pieces of
the ventricular septum were removed during the surgical
correction of outﬂow track hypertrophy.
A schematic of experimental design for the study of
frequency-dependent drug effects is given in Figure 1.
Stimulation frequency was increased in 1-Hz steps up to 5ents in human atrial trabeculae. A: Time-matched control experiments: after
e refractory period was measured (b). Stimulation rate was then increased
nt of effective refractory period (b). B: After returning to 1 Hz, preparations
rate increases.
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stimulus delivered after trains of 10 regular pulses with
decreasing intervals in 5-ms steps until the extrastimulus
failed to excite. Time-matched control (TMC) experiments
in the absence of the drug or in the presence of vehicle
(dimethyl sulfoxide [DMSO]) were conducted in a similar
manner to assess time-dependent changes associated with the
length of the experiment (“run-up/run-down”). Since no
differences were detected between the 2 groups, the results
were pooled.
The following AP parameters were analyzed: resting
membrane potential (RMP, in mV); action potential ampli-
tude (APA, in mV); APD at 20%, 50%, and 90% of
repolarization (APD20, APD50 and APD90, in ms); maximum
rate of depolarization; maximum upstroke velocity (dV/
dtmax, in V/s); and plateau potential (deﬁned as the mean
absolute membrane potential [in mV] in the time window
between 20% and 30% of APD90 [PLT20]). Preparations with
resting potentials less negative than 65 mV and amplitudes
below 85 mV were discarded.
Stock solutions and drug application
Aliquots of 10 mM XEN-D0103 stock solution (in DMSO)
were added directly to the reservoir of the circulating
solution. The DMSO concentration never exceeded 0.2%,
which did not induce changes when applied alone.
Corrected QT interval evaluation in healthy
volunteers
A double-blind, randomized, placebo-controlled phase 1
single ascending dose study was performed in healthy male
volunteers to determine the safety and tolerability of XEN-
D0103 and to examine the relationship between the drug
plasma concentration and the corrected QT (QTc) interval
(for details, see Online Supplemental Methods). Doses
investigated were 10, 30, 60, 120, and 200 mg of XEN-
D0103. An assay of plasma XEN-D0103 was performed
using a high-performance LC-MS/MS. The lower limit of
quantiﬁcation for the assay was 0.5 ng/mL. Safety electro-
cardiographic (ECG) telemetry (2-lead ECG) was monitored
continuously from dosing until 24 hours after doing to
monitor heart function and detect proarrhythmic events in
real time.
Statistical analysis
For statistical analysis, drug effects on relative AP parame-
ters (ΔERP, ΔAPD90, and ΔPLT) were compared with
TMCs using an unpaired Student t test. Drug effects on
absolute AP parameters were compared with predrug effects
using a paired Student t test (Online Supplemental Tables
S2–S7). Within 1 group, the frequency-dependent changes
were analyzed using a repeated-measures analysis of var-
iance (ANOVA) followed by Bonferroni multiple compar-
ison test. Data are typically presented as mean  standard
error of the mean, and 95% conﬁdence intervals are given,
where appropriate.Concentration-effect modeling was performed for QTcF
(QT interval corrected by the Fridericia formula) evaluation
in healthy volunteers, with ΔΔQTcF intervals being
regressed onto the plasma concentrations of XEN-D0103
at the exact times as the continuous 12-lead ECGs. The effect
of XEN-D0103 plasma concentration on ΔΔQTcF was
investigated using a regression model and ANOVA. At each
time of stable supine rest, XEN-D0103 plasma concentration
was interpolated using nonparametric superposition. A
mixed-effects model that included plasma concentration,
treatment group, and an interaction between plasma concen-
tration and treatment group as ﬁxed factors and subject as a
random factor was evaluated.Results
Effects of XEN-D0103 on human cardiac APs and ERP
APs from patients in SR Figure 2 (upper panel) displayed the
typical spike-and-dome shape.15 The concentration-
dependent effects of XEN-D0103 (0.3–10 mM; Online
Supplemental Figure S1) on SR APs at the basal stimulation
frequency of 1 Hz showed that XEN-D0103 produced robust
effects on electrophysiological parameters, consisting of a
prominent elevation of the plateau accompanied by short-
ening of APD90. The maximum effects were reached within
40–50 minutes.Effects of stimulation frequency on APs and ERP in
SR and AF
In the absence of the drug, APs and ERP from patients in SR
shortened with increasing stimulation rate, as reported by
others.16 This adaptation response was attenuated in AF
preparations (Online Supplemental Figure S2). ERP values
and AP parameters (at 1–5 Hz) for SR, cAF, and pAF
experiments and TMC experiments are summarized in
Online Supplemental Tables S2–S7. A lager fraction of SR
preparations than of AF preparations failed to follow 5 Hz,
and since measurements of ERP were more prone to failures
than were measurements of other AP parameters, numbers
for ERP values are still lower at 4 and 5 Hz.Effects of XEN-D0103 on APs and ERP in atrial tissue
from patients in SR
In SR preparations, the ERP/APD90 shortening effect of
XEN-D0103 (3 mM) at 1 and 2 Hz was converted into a
signiﬁcant prolonging effect at 3 and 4 Hz (Figure 2, upper
panel, and Figure 3) and excitability was suppressed in the
presence of the drug at 5 Hz.
Although the typical “spike-and-dome” shape of the SR
AP converted to a triangular AF-like shape at 4 Hz, the
maximum effect of XEN-D0103 on the plateau potential
(ΔPLT20, Figure 3, lower left panel) was similar at all
frequencies while APD20 and APD50 were both signiﬁcantly
prolonged at all frequencies tested. RMP was not altered by
XEN-D0103 (see Online Supplemental Table S2); however,
a reduction in dV/dtmax was observed.
Figure 2 Frequency dependence of XEN-D0103 effects (3 mM). Original traces of action potentials recorded in right atrial trabeculae from patients in sinus
rhythm (SR), chronic atrial ﬁbrillation (cAF), and paroxysmal AF (pAF). c, Predrug control; red line, in the presence of XEN-D0103. The red dashed line in the
top-right panel indicates failure to follow stimulation at this rate in the presence of the drug. Calibration bars as indicated.
Heart Rhythm, Vol 13, No 2, February 2016558The results of TMC experiments revealed a trend toward
shortening of APD90 over the course of the experiment, as
such the drug-induced prolongation of APD90 at 3 and 4 Hz
is likely to be underestimated and the shortening of APD90
at lower pacing frequencies of 1 and 2 Hz may be
overestimated. Data were not corrected for run-down
because experiments were conducted in different tissue
preparations.Effects of XEN-D0103 on APs and ERP in atrial tissue
from patients in cAF
In cAF trabeculae, XEN-D0103 also signiﬁcantly elevated
the PLT20 (Figure 2, middle panel). The increase in PLT20
was smaller compared to SR preparations and somewhat
decreased with increasing stimulation frequencies (Figure 4),
but in contrast to SR, XEN-D0103 prolonged APD at the 3
repolarization levels analyzed (prolongation statistically
signiﬁcant for APD90 at 2 Hz and for APD50 and APD20 at
all frequencies tested) (Online Supplemental Table S4). APA
was signiﬁcantly increased at 1 Hz; RMP was signiﬁcantly
more negative at 1–4 Hz; and dV/dtmax was similar in the
absence and presence of the drug at all frequencies (Online
Supplemental Table S4).
With 3 mM XEN-D0103, ERP was signiﬁcantly pro-
longed at all frequencies but only reached statistical signiﬁ-
cance at 2 Hz (Figure 4, left upper panel, and Online
Supplemental Table S4). Similar to the results in SR tissue,
ERP and APD90 shortened with time in TMC experiments
(Online Supplemental Table S5), as such leading to the
underestimation of drug effects on ERP and APD90.Effects of XEN-D0103 on APs and ERP in atrial tissue
from patients in pAF
The APs recorded from pAF tissue displayed a spike-and-
dome shape similar to that seen in SR tissue (Figure 2, lower
panel). In pAF tissue, XEN-D0103 (3 mM) produced
frequency-dependent effects similar to those in SR tissue
(Figure 5). APA and RMP were not affected by XEN-
D0103, but dV/dtmax was reduced in the presence of XEN-
D0103 at 1–4 Hz (Po .05; Online Supplemental Table S6).
PLT20 was elevated at all frequencies, and APD90 was
shortened at 1 Hz and even slightly prolonged at 5 Hz
(Figure 5). In the presence of the drug, only 4 and 1 of 6
preparations could be stimulated at 4 and 5 Hz, respectively
(Online Supplemental Table S6), similar to SR tissue,
whereas 5 and 3 of 6 trabeculae followed these rates in
TMC (Online Supplemental Table S7).
ERP signiﬁcantly decreased in pAF tissue at the stim-
ulation frequency of 1 Hz. This effect was diminished at 2 Hz
and turned into a slight, though nonsigniﬁcant, prolongation
at 3 and 4 Hz. In TMC pAF preparations, ERP tended to
shorten from 1 to 4 (Figure 5 and Table S7).Effects of XEN-D0103 on human ventricular AP
parameters
For comparison purposes and for conﬁrming the atrial
selectivity of XEN-D0103, APs were recorded from 3 human
ventricular septum preparations. XEN-D0103 (10 mM) had
no signiﬁcant effect on human ventricular AP parameters
(Online Supplemental Figure S3).
Figure 3 Frequency-dependent effects of XEN-D0103 in right atrial trabeculae from patients in sinus rhythm (SR). Effects on effective refractory period
(ERP), action potential duration at 90% repolarization (APD90), and plateau potential (deﬁned as the mean absolute membrane potential [in mV] in the time
window between 20% and 30% of APD90 [PLT20]) depicted as the difference between predrug control and in the presence of the drug (delta values). Note that in
SR, none of the preparations followed stimulation at 5 Hz in the presence of XEN-D0103. Separate time-matched control (TMC) experiments without drug
application are shown on the right side. Delta values in the presence of the drug were compared with the corresponding TMC data at each frequency using an
unpaired Student t test. The results of this comparison are shown as ##Po .01 and ###Po .0001. Delta values at each frequency (1–3 Hz) in the presence of the
drug were compared in a group to determine frequency-dependent drug effects using a repeated-measures analysis of variance (results shown as a line, comparing
1–3 Hz) with a Bonferroni posttest (results shown in the inset). Failure to capture action potentials in all preparations at 5 Hz precluded comparison of this group
using a repeated-measures test.
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induced proarrhythmia in healthy human subjects
Comprehensive ECG recordings and ECG analysis were
performed in a phase 1 clinical trial to determine whether
XEN-D0103 prolongs the QTc interval in humans. As no
meaningful change in heart rate (HR) was noted during the
study, the Fridericia formula was used to correct the QT
interval for the HR (QTcF). A plot of XEN-D0103 plasma
concentration vs ΔΔQTcF is shown in Figure 6, and most
notably, XEN-D0103 plasma concentrations reached 7000
ng/mL in some volunteers without increasing ΔΔQTc.
A categorical analysis of QT interval and QTcF was
performed, and no subjects receiving an active treatmenthad a QT interval or QTcF 4450 ms, or increase in QTcF
from baseline 430 ms. In addition to 12-lead Holter
monitoring, 2-lead ECG telemetry monitoring was performed
for 24 hours after dosing. All results of ECG telemetry were
considered as normal by the investigator. There were no
clinically signiﬁcant changes, including induction of AF or
ventricular proarrhythmia after XEN-D0103 dosing. No
dose-related effects on PR interval, QRS complex, and HR
as well as on T-wave and U-wave morphologies were noted.
Discussion
We have investigated the effects of the novel highly selective
IKur/Kv1.5 inhibitor XEN-D0103 (Servier S66913) on AP
Figure 4 Frequency-dependent effects of XEN-D0103 in right atrial trabeculae from patients in chronic atrial ﬁbrillation (cAF). Layout as in Figure 3. Delta
values in the presence of the drug were compared with the corresponding time-matched control data at each frequency using an unpaired Student t test. The
results of this comparison are shown as #Po .05 and ###Po .0001. Note that repeated-measures analysis of variance with Bonferroni posttest did not result in
any statistically signiﬁcant differences between 1, 2, and 3 Hz. Abbreviations as in Figure 3.
Heart Rhythm, Vol 13, No 2, February 2016560parameters and ERP over a pathophysiological relevant
range of frequencies (1–5 Hz). Our major ﬁnding was that
XEN-D0103 prolonged APD and ERP preferentially at high
stimulation rates in SR and pAF preparations, providing
novel mechanistic information on modulating IKur that is
likely to be highly desirable for treating pAF.
In accordance with the literature,15,17,18 electrical remod-
eling during cAF caused triangulation of the AP shapes.
Atrial tissue from patients in pAF was apparently not
electrically remodeled since APs still exhibited the typical
SR-like spike-and-dome conﬁguration. We also found that
atrial APD and ERP shortened with increasing frequency of
stimulation, which has been related mainly to decrease in
L-type Ca2þ current,19 and that adaptation to high rates was
attenuated in preparations from patients in cAF.15,16
The maximum rate of depolarization dV/dtmax declined
signiﬁcantly at high rates16 because of the incompleterestoration of RMP with an increasing number of prepara-
tions failing to capture stimulation, thereby limiting fre-
quency testing to 5 Hz.
Channels conducting the human cardiac IKur are encoded
by the Kv1.5 gene KCNA5, which is strongly expressed in
atria, and although small amounts of messenger RNA have
been reported in human ventricular tissue, no functional
current has been reported.20 Consequently, IKur block
exhibits an atrial-selective effect on cardiac repolarization
and could be considered a drug intervention suited for the
treatment of atrial rhythm disturbances without unwanted
effects on ventricular function. This is suggested by the lack
of impact of XEN-D0103 on ventricular AP. The absence of
XEN-D0103–induced QTc prolongation as well as PR and
QRS changes and the absence of arrhythmias, including AF,
in healthy volunteers observed in the clinical study conﬁrms
the ﬁnding previously reported for XEN-D01019 and
Figure 5 Frequency-dependent effects of XEN-D0103 in right atrial trabeculae from patients in paroxysmal atrial ﬁbrillation (pAF). Layout as in Figure 3.
Delta values in the presence of the drug were compared with the corresponding time-matched control data at each frequency using an unpaired Student t test. The
results of this comparison are shown as #Po .05, ##Po .01, and ###Po .0001. Group comparison of delta values (1–3 Hz) in the presence of the drug as in
Figure 3. Abbreviations as in Figure 3.
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being present and functional in the human atria and not the
ventricle.
The characteristic changes in electrophysiological param-
eters observed with XEN-D0103 in human right atrial
trabeculae (1 Hz) are consistent with block of Kv1.5 channels
as previously reported for this14 and other less selective
drugs (eg, 4-AP,7,21,22 DPO-1,23 AVE0118,8 XEN-D0101,9
and MK-044810). These drugs elevated the plateau potential
in SR preparations and signiﬁcantly shortened APD90 at 1 Hz
but prolonged APD90 in cAF trabeculae. The shortening of
APD90 and ERP by Kv1.5 inhibitors in SR is proposed to be
caused by the marked elevation of the plateau potential into a
voltage range where more hERG channels are activated, and
although they inactivate rapidly, they can recover from
inactivation at more negative potentials and thus hasten ﬁnal
repolarization.24 Since the most prominent effects of XEN-D0103 were elevation of PLT20, shortening of APD90 in SR
at 1 Hz, and prolongation of APD20, APD50, APD 90 in cAF,
we conclude that XEN-D0103 does block IKur in human
atrial trabeculae. Furthermore, these characteristic electro-
physiological changes appear to be a dominant class effect of
IKur block, since they are observed with XEN-D0103 as well
as with other less selective Kv1.5 inhibitors.
Interestingly, in SR preparations, the APD shortening
effect of XEN-D0103 at the basal frequency of 1 Hz turns
into an APD-prolonging effect accompanied by an increase
in ERP at the higher stimulation rates of 3 and 4 Hz
(Figure 3). In addition, fewer preparations could be stimu-
lated at 4 Hz and excitation failed in all SR preparations at 5
Hz in the presence of XEN-D0103. In pAF, similar effects
were observed, the PLT20 increased at all frequencies, and
ERP was prolonged at 3–4 Hz (although this effect was
signiﬁcant only at 3 Hz) with all but one preparation failing
Figure 6 Baseline- and placebo-adjusted QTcF (ΔΔQTcF) values plotted
against XEN-D0103 plasma concentration derived from healthy volunteers
(n ¼ 63). Concentration effect modeling showed no evidence of a relation-
ship between the plasma concentration of XEN-D0103 (in ng/mL) and
ΔΔQTcF (in ms) in healthy volunteers orally dosed with XEN-D0103.
QTcF ¼ QT interval corrected by the Fridericia formula.
Heart Rhythm, Vol 13, No 2, February 2016562to capture excitation at 5 Hz. These qualitatively similar
responses suggest that tissue from patients in SR may be a
useful surrogate for investigating the effects of drugs in pAF,
especially given the scarcity of tissue from patients in pAF.
The data in SR and pAF tissue provide novel evidence in
support of IKur/Kv1.5 as a target for the management of pAF.
In cAF, qualitatively different effects were observed
compared with those seen in SR and pAF. All but one
preparation followed stimulation at 5 Hz both in the absence
and in the presence of XEN-D0103. The ability to pace the
cAF tissue at high frequencies suggests a remodeled phenotype
that forms the substrate for the initiation and perpetuation of
the arrhythmia in these patients. The shorter APD90 and ERP
and the more negative RMP of cAF tissue have previously
been reported by us and others9,11,16,25–27,30 at 1 Hz. This is
likely to contribute to the ability of cAF tissue to capture higher
stimulation frequencies, in the absence and presence of the
drug, than to the ability of SR or pAF tissue because of the
higher availability of Naþ channels at more negative mem-
brane potential. In cAF tissue, XEN-D0103 prolonged the
APD at all frequencies but effects on the ERP were signiﬁcant
only at 2 Hz. However, the TMC data suggest this was
underestimated at all frequencies tested. Despite these effects
on AP parameters in cAF preparations, we do not expect block
of Kv1.5 channels by XEN-D0103 to convert cAF back to SR
because of electrical and structural remodeling.6 Nevertheless,
this effect may protect the atrial myocardium during the phase
of reverse remodeling after cardioversion.
At present, it is not known whether and how block of IKur
is related to ERP. We speculate that the primary reduction inIKur can cause a secondary effect on Na
þ conductance,
leading to increased postrepolarization refractoriness rather
than having a direct effect on the cardiac Naþ channel. This
is supported by the lack of effect on the recombinant peak
Nav1.5 current at concentrations up to 10 μM.14 Given the
lack of a direct effect on Naþ channels, the increase in
postrepolarization refractoriness 28,29 may be due to an
indirect effect on Naþ channel availability owing to the
marked change in the proﬁle of the AP in the presence of the
drug (ie, elevated plateau and triangulation of the AP
shapes). However, this is speculative and further experi-
ments are needed to clarify the mechanism of ERP modu-
lation by XEN-D0103, but these are outside the scope of the
present study. In any case, it is seems highly desirable to
increase ERP in both SR and pAF to disrupt reentry and
prevent AF recurrence. This, in turn, may be expected to
facilitate the reverse remodeling process after cardioversion.
Pharmacological interventions for interrupting microreentry
have to prolong the ERP, while suppression of ectopic foci
requires reduction of excitability. Given the pharmacological
proﬁle of XEN-D0103, it is more likely to increase atrial
refractoriness than to reduce excitability.
It should be noted that although the reported effect of
XEN-D0103 in cAF appears small, prolongation of ERP
may be underestimated because of the concomitant reduction
of ERP observed in TMC. A broader comparison to other AF
antiarrhythmic drugs was not possible, as they would require
evaluation using the methodology that evaluated APD
parameters and ERP in SR and AF tissue at multiple pacing
frequencies as well as assessment of the effect on ventricular
tissue to conﬁrm atrial selectivity. More importantly, the
present data suggest some beneﬁts of XEN-D0103 in pAF.
A lack of effect of other IKur inhibitors in healthy volun-
teers13 could be due to the rather long cycle lengths (ie,
4400 ms) used. According to our data, we would not have
expected a prolonging effect of MK-0448 on atrial ERP at
cycle lengths below 333 ms (3 Hz). Last but not least,
although IKur had been originally discovered in dog atria, IKur
could no longer be demonstrated during the past years31;
hence, the absence of any effect of IKur inhibitors in dog
models of AF is not surprising. In conclusion, we found the
use of IKur inhibitors in treating AF that includes both pAF
and recent-onset persistent AF, that is, AF ofo6 months of
duration.
Our data highlight the importance of pathophysiologically
relevant pacing frequencies (SR and pAF) and an arrhyth-
mogenic substrate (ionic and structural remodeling in cAF).
Only at higher pacing frequencies in SR and pAF and at 2
and 3 Hz in cAF tissue did we observe signiﬁcant increases
in APD/ERP. On the basis of our results, we expect XEN-
D0103 to be preferentially effective in non-remodeled atrial
tissue (SR and pAF). The positive frequency dependence of
ERP prolongation and loss of excitability at high frequencies
(5 Hz) in SR preparations and an essentially similar pattern
of effects in pAF suggest that IKur inhibitors could be
effective for the termination of recent-onset AF (ie, suppres-
sion of high-frequency ﬁring) and reduction of AF burden in
563Ford et al Frequency-Dependent Effects of the IKur Inhibitor XEN-D0103pAF before electrical and structural remodeling has taken
place.
To date, no clinical trials have been published on a
selective human IKur inhibitor in a patient population with
AF; however, based on these novel mechanistic ﬁndings for
XEN-D0103, it is currently being evaluated in 2 phase 2
clinical studies to evaluate the therapeutic potential of a
selective IKur inhibitor to prevent recurrences in patients in
pAF. They both started in 2014.
The ﬁrst trial (EudraCT no. 2013-004456-38) was a
double-blind, randomized, placebo-controlled, crossover
study assessing a single-dose level (150 mg twice daily) of
XEN-D0103 in patients in pAF and patients with implanted
pacemakers. The primary objective was to assess the
reduction in AF burden over 28 days compared to placebo.
The second phase 2 study in patients in pAF called
DIAGRAF-IKUR (EudraCT no. 2013-004456-38) aimed
to evaluate the efﬁcacy of 3 doses of XEN-D0103
(S66913), vs placebo on AF and/or atrial tachycardia burden
(AF/AT burden) in patients who have an indication for AF
ablation and are implanted with insertable cardiac monitoring
device.Study limitations
In most of the preparations, basic parameters slightly
declined with time. The classiﬁcation of patients into SR
and AF groups is not always reliable; that is, the SR group
may include atrial tissue from patients that have had
unrecognized episodes of pAF or recent-onset AF. Further-
more, cAF tissue will include patients in permanent AF who
are known to be refractory to SR-maintenance therapy.Conclusion
The selective IKur inhibitor XEN-D0103 consistently elevated
the AP plateau in human atrial trabeculae irrespective of the
initial shapes of the control APs and whether the preparations
originated from patients in SR, pAF, or cAF. In SR and pAF
preparations, the APD shortening effect observed at 1 Hz
resulted in prolongation of APD90 and ERP at high stimulation
rates with loss of excitability at 5 Hz, whereas in cAF
preparations, ERP prolongation was modest. For the prevention
of AF recurrence, frequency-dependent prolongation of ERP by
XEN-D0103 in both SR and pAF preparations is a highly
desirable mode of action that may protect the atrial myocardium
during the phase of reverse remodeling after cardioversion.
These data warrant the evaluation of XEN-D0103 in a clinical
trial in patients in pAF.Acknowledgments
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Pharmacological treatment of atrial ﬁbrillation (AF) remains a clinical challenge owing to the lack of effective and safe
drugs. The selective blockers of Kv1.5 channels were designed to ﬁll this gap, yet their antiarrhythmic effects are yet to be
reported in a clinical setting. To date, most Kv1.5 blockers have been shown to prolong only action potential duration
(APD) and effective refractory period (ERP) at physiological beating rates in atrial tissue remodeled by persistent AF,
whereas they actually shortenAPD and ERP in sinus rhythm (SR) tissue. However, little is known about their efﬁcacy at the
high rates of excitation encountered during AF. Here we report that the highly selective Kv1.5 channel blocker XEN-D0103
prolongs APD and ERP measured with sharp microelectrodes in human right atrial trabeculae from patients in chronic AF
in the frequency range 1–5 Hz. In trabeculae from patients in SR and paroxysmal AF, the ADP-shortening effect of
XEN-D0103 at low stimulation rate (1 Hz) turns into APD prolongation at high rates, leading to failure of excitation
response. We conclude that the XEN-D0103 exhibits positive frequency–dependent electrophysiological effects that could
be clinically useful, because prolongation of APD and suppression of action potentials by XEN-D0103 at high stimulation
rates in SR and paroxysmal AF tissue is expected to reduce AF burden. This concept needs to be conﬁrmed in clinical trials.
Our data cannot provide evidence for preventing recurrence or termination of permanent AF by XEN-D0103. This must be
tested in appropriate models.
